Revenue Update on Insulet Corporation(NASDAQ:PODD)

Insulet Corporation(NASDAQ:PODD) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $87.33M. Analysts estimated a revenue of $81.19M. Earnings per share were $-0.08. Analysts had estimated an EPS of $-0.17.

Insulet Corporation (PODD) made into the market gainers list on Fridays trading session with the shares advancing 0.30% or 0.13 points. Due to strong positive momentum, the stock ended at $42.99, which is also near the day’s high of $43.01. The stock began the session at $42.93 and the volume stood at 3,61,954 shares. The 52-week high of the shares is $44.42 and the 52 week low is $23.94. The company has a current market capitalization of $2,462 M and it has 5,72,67,862 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On May 27, 2016, Regina O Sommer (director) sold 8,019 shares at $30.42 per share price.Also, On May 19, 2016, Patrick J Sullivan (CEO) purchased 45,000 shares at $26.98 per share price.On May 16, 2016, Bradley A Thomas (EVP Human Resources) purchased 2,975 shares at $26.63 per share price, according to the Form-4 filing with the securities and exchange commission.

Insulet Corporation is a medical device company engaged in the development manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System) an insulin infusion system for people with insulin-dependent diabetes. The Company’s principal offices are located in Billerica Massachusetts. Features of the OmniPod System include two-part design no tubing and automated cannula insertion. The OmniPod System consists of two devices that communicate wirelessly: the OmniPod a small lightweight disposable insulin infusion device worn beneath clothing; and the PDM a handheld device much like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions. The OmniPod will operate up to 72 hours (but no more than 80 hours) after it is first activated. The OmniPod System does not have external tubing and features an automated hands-free cannula insertion system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Insulet Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Insulet Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.